Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
AstraZeneca Pharma India Limited ( (IN:ASTRAZEN) ) has provided an announcement.
AstraZeneca Pharma India Limited has received a draft order from the Income Tax Department regarding transfer pricing issues for the assessment year 2022-23. The company plans to challenge this order before the Dispute Resolution Panel, with the quantum of the claim being approximately Rs. 11.96 crores, excluding interest and penalties. The financial implications of this draft order are yet to be determined, pending the final assessment.
More about AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited operates in the pharmaceutical industry, focusing on the development and commercialization of prescription medicines. The company is a part of the global AstraZeneca group, which is known for its innovative medicines across various therapeutic areas.
YTD Price Performance: 10.02%
Average Trading Volume: 1,584
Current Market Cap: 198.2B INR
For an in-depth examination of ASTRAZEN stock, go to TipRanks’ Stock Analysis page.